GLP-1 receptor agonists are rewriting what's possible in weight management. The clinical trial data is unlike anything seen before in obesity medicine — and it's available now through a licensed physician online.
Free consultation — a clinician responds within 24 hours.
A clinician from Elevation Health will be in touch soon.
These aren't scare tactics. They're peer-reviewed facts from the CDC and NIH that show exactly why effective weight management is one of the most important health decisions you can make.
CDC BRFSS Data 1990–2023 · Adult prevalence (%)
CDC / NHANES 2017–2020 · Most recent available survey data
Published peer-reviewed clinical trial data. Individual results vary.
NEJM SELECT Trial 2023 · Semaglutide 2.4mg · N=17,604 · 3.3 yr follow-up
These risks aren't hypothetical. They're documented health outcomes associated with obesity — from peer-reviewed research and federal health agencies.
Adults with obesity are approximately 7 times more likely to develop type 2 diabetes than those at a healthy weight. GLP-1 medications were originally developed to address this exact pathway.
People with obesity have roughly twice the risk of coronary heart disease. The SELECT trial demonstrated that GLP-1 therapy may directly address this — reducing cardiovascular events by 20%.
Obesity is associated with a roughly 50% increased risk of ischemic stroke. Blood pressure, insulin resistance, and vascular inflammation are all contributing factors that GLP-1 therapy may help address.
The CDC and NIH have identified 13 types of cancer associated with overweight and obesity — including breast, colon, endometrial, kidney, and pancreatic cancer. Excess body fat is a documented carcinogen driver.
Obesity is the single largest risk factor for obstructive sleep apnea. Neck fat, airway tissue, and breathing mechanics are all affected. Weight loss via GLP-1 therapy may significantly reduce apnea severity.
Each pound of excess body weight adds approximately 4 pounds of pressure on the knee joints. Obesity is one of the strongest modifiable risk factors for osteoarthritis and joint replacement surgery.
These aren't before-and-after photos. They're peer-reviewed randomized controlled trials published in the New England Journal of Medicine.
For decades, the best available medications produced 5–8% body weight loss on average. GLP-1 receptor agonists have shattered that benchmark — with semaglutide averaging ~15% and tirzepatide averaging ~20–22% in published trials.
More importantly: these aren't just weight loss drugs. They also improve blood sugar control, reduce blood pressure and cholesterol, and — as the SELECT trial showed — meaningfully reduce cardiovascular events.
The best outcomes occur when GLP-1 medication is combined with a structured clinical support program. That's why Elevation Health's online weight loss clinic pairs every GLP-1 protocol with a registered dietitian-led 12-week lifestyle plan — addressing both the biology and the behavior.
All products require a physician consultation and are dispensed by a licensed U.S. compounding pharmacy. Batch tracked with certificates of authenticity.
The original GLP-1 blockbuster. Same active molecule as Ozempic/Wegovy — compounded for significant cost savings. STEP-1 trial: ~15% average weight loss.
⚕️ Physician consult ($99) billed separately
The dual agonist that outperformed semaglutide in head-to-head data. Same molecule as Mounjaro/Zepbound. SURMOUNT-1 trial: up to ~22% weight loss.
⚕️ Physician consult ($99) billed separately
Triple receptor action — GLP-1, GIP, and glucagon simultaneously. Phase 2 trial data showed ~24% average weight loss. The most advanced metabolic peptide available.
⚕️ Physician consult ($99) billed separately
No fluff. No marketing speak. Just clear answers backed by clinical data.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) publishes comprehensive, non-commercial educational content on FDA-approved medications for weight management — an authoritative resource for patients considering GLP-1 therapy.
Read NIH NIDDK Weight Loss Medication Guide →Elevation Health's physician-supervised program combines real GLP-1 medication with a personalized dietitian-built plan. Everything online. Everything included.
A clinician will be in touch shortly.